COMPASS Pathways (CMPS) Could Be 62% Undervalued As FDA Filing Sharpens The Case
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
Compass Pathways PLC (CMPS) (Q3 2026) Earnings Call Highlights: $444 Million Cash Runway, FDA ...
Compass Pathways stock gains on FDA filing for depression drug
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
Compass Pathways Submits FDA New Drug Application For Comp360 Psilocybin For Treatment-Resistant Depression
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $65 Price Target
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is COMPASS Pathways (CMPS) Pricing In Too Much On Book Value?
Wells Fargo Maintains Equal-Weight on Compass Pathways, Lowers Price Target to $10
How Investors May Respond To COMPASS Pathways (CMPS) Smaller Loss And FDA Progress
Compass Pathways: 3 Key Takeaways for Long-Term Investors
Compass Pathways (CMPS) Q3 2026 Earnings Call Transcript
Compass Pathways Q3 Earnings Call Highlights
Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027
COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
Compass Pathways (NASDAQ:CMPS) Narrows Q3 Loss as Final NDA Submission Nears
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
BTIG Reiterates Buy on Compass Pathways, Maintains $25 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.